NeoGenomics (NEO) Q4 2024 Earnings Transcript

NeoGenomics reported Q4 revenue of $172 million, up 11%, with adjusted EBITDA rising 27% to $12 million and adjusted gross margin expanding to 48%, the highest in 20 quarters. Full-year 2024 revenue reached $661 million, up 12%, while adjusted EBITDA improved to $40 million from a negative $48 million in 2022; the company also raised 2025 guidance to $735 million-$745 million revenue and $55 million-$58 million adjusted EBITDA. Management highlighted continued NGS growth, new product launches including PanTracer and an HRD upgrade, and plans to repay $201 million of convertible notes from cash and securities, though pharma revenue softness and RaDaR litigation remain key risks.

Analysis

NEO is transitioning from a turnaround story to a self-funded compounder, and the market is likely still underappreciating how much of the 2025 setup is product-cycle rather than pure macro. The key second-order effect is that commercial expansion and interface integration should improve retention and switching costs, which makes the revenue base more durable than headline volume growth implies. If the company executes on the second-half launch slate, the mix shift into higher-value NGS and liquid biopsy can create an operating leverage step-up even if core clinical growth only stays mid-single digits.

The bigger strategic issue is that NEO is trying to reprice itself from a general lab to a platform with embedded workflow and MRD optionality. That matters because partnerships like Adaptive can pull in adjacent traffic without requiring a wholesale spend race against larger diagnostics peers; the channel itself becomes the moat. The flip side is that pharma/non-clinical remains a weak spot, and litigation around RaDaR keeps the valuation tied to a binary legal overhang through October, so the stock may oscillate between “quality growth” and “headline risk” depending on trial commentary.

Consensus still seems too focused on the revenue guide rather than the margin trajectory. The more important variable is whether gross margin gains from automation, mix, and reimbursement hold while sales capacity ramps, because that determines how much of the 2026 story can be financed internally. If management can preserve the current cadence of product launches and avoid a post-launch reimbursement lag, the setup supports multiple expansion; if not, the stock likely de-rates back toward a low-growth diagnostics multiple despite the optimistic narrative.

Key Decisions for Investors

• Long NEO into Q2-Q3 2025 on pullbacks: risk/reward favors owning the product-launch and margin inflection ahead of the second-half revenue ramp; use a 6-9 month horizon and size for litigation headline volatility.
• Buy NEO Jan-2026 or Jan-2027 call spreads on weakness: upside is tied to successful PanTracer adoption and improved 2H execution, while downside is capped if RaDaR litigation drags but core clinical remains intact.
• Pair trade: long NEO / short NTRA for 3-6 months if you want to express relative margin expansion and self-funded growth versus a more mature competitor with less incremental operating leverage.
• Avoid chasing the stock immediately ahead of October 2025 RaDaR trial dates; expect elevated implied volatility and use any selloff after unfavorable legal headlines as the better entry point.
• If you need lower-risk exposure, overweight NEO only against a basket of slower-growth diagnostics names rather than outright beta, since the company-specific product cadence is the real driver of alpha.